Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

NCT01272557 is registered in ClinicalTrials.gov with PD Dr. med. Matthias Dollinger as lead sponsor.

NCT NCT01272557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01272557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Lead sponsor
PD Dr. med. Matthias Dollinger
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2010
Completion date
December 31, 2014
Enrollment
170 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

liver carcinoma